// App-Quantinova.ai

BSH2020‐PO‐089 : Brentuximab vedotin plus chemotherapy for stage III/IV classical Hodgkin lymphoma: 4‐year update of the ECHELON‐1 study

Researchers

Presenter

  • J. Radford

Principal Investigators

  • D. Straus

  • M. Dlugosz-Danecka

  • S. Alekseev

  • . Ills

  • E. Lech-Maranda

  • T. Feldman

  • P. Smolewski

  • K. Savage

  • J. Walewski

  • R. Ramchandren

  • P. L. Zinzani

  • M. Hutchings

  • J. Connors

  • J. Munoz

  • W. S. Kim

  • R. Advani

  • S. Ansell

  • A. Younes

  • A. Gallamini

  • H. Miao

  • R. Liu

  • K. Fenton

  • A. Forero-Torres

  • M. Picardi

Medical Centers

  • The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

  • Washington University School of Medicine, St. Louis, MO

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • National Institute of Oncology, Kraków, Poland

  • NN Petrov Research Institute of Oncology, St Petersburg, Russia

  • Division of Endocrinology, Department of Medicine, University of Debrecen, Debrecen, Hungary

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • John Theurer Cancer Center, Hackensack, NJ

  • Medical University of Lodz, Lodz, Poland

  • BC Cancer Centre for Lymphoid Cancer and Department of Medical Oncology,Vancouver,Canada

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • University of Tennessee, Knoxville, TN

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Rigshospitalet, Copenhagen, Denmark

  • BC Cancer Centre for Lymphoid Cancer,Vancouver,Canadá

  • Banner MD Anderson Cancer Center Clinic, Gilbert, AZ

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Stanford University Cancer Institute, Stanford, CA

  • Mayo Clinic, Rochester, MN

  • Antoine Lacassagne Center, Nice, France

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Seattle Genetics, Bothell, WA

  • Seattle Genetics, Seattle, WA

  • Hematology Department,II University Federico II,Naples,Italy

Locations

  • United Kingdom

  • United States

  • Poland

  • Russia

  • Hungary

  • Canada

  • Italy

  • Denmark

  • France

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Peripheral Nervous System

Disease

  • Hodgkin's Lymphoma

  • Peripheral neuropathy

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

  • dacarbazine Intravenous

  • Vinblastine

  • Doxorubicin

  • Bleomycin

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

Phase

  • III

Study Id's

  • NCT01712490

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved